Barclays PLC Summit Therapeutics Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 250,118 shares of SMMT stock, worth $4.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

250,118

Previous 387,313 35.42%

Holding current value

$4.75 Million

Previous $3.02 Million 81.3%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$6.89 - $31.93 $945,273 - $4.38 Million	-137,195 Reduced 35.42%	250,118 $5.48 Million
Q2 2024 Aug 14, 2024	SELL	$2.39 - $10.92 $14,337 - $65,509	-5,999 Reduced 1.53%	387,313 $3.02 Million
Q1 2024 May 15, 2024	BUY	$2.55 - $5.07 $190,604 - $378,967	74,747 Added 23.46%	393,312 $1.63 Million
Q4 2023 Feb 15, 2024	BUY	$1.67 - $2.83 $284,816 - $482,653	170,549 Added 115.22%	318,565 $831,000
Q3 2023 Nov 07, 2023	BUY	$1.54 - $2.42 $153,605 - $241,380	99,744 Added 206.63%	148,016 $277,000
Q2 2023 Aug 03, 2023	SELL	$1.32 - $2.81 $261,613 - $556,919	-198,192 Reduced 80.41%	48,272 $120,000
Q1 2023 May 04, 2023	BUY	$1.38 - $5.41 $320,994 - $1.26 Million	232,605 Added 1678.37%	246,464 $432,000
Q4 2022 Feb 13, 2023	BUY	$0.68 - $5.31 $8,003 - $62,498	11,770 Added 563.43%	13,859 $59,000
Q3 2022 Nov 03, 2022	BUY	$0.89 - $1.63 $855 - $1,566	961 Added 85.2%	2,089 $2,000
Q2 2022 Aug 12, 2022	SELL	$0.92 - $2.38 $2,974 - $7,694	-3,233 Reduced 74.13%	1,128 $1,000
Q1 2022 May 16, 2022	BUY	$2.0 - $3.45 $8,722 - $15,045	4,361 New	4,361 $11,000

Others Institutions Holding SMMT

# of Institutions

193

Shares Held

75.8M

Call Options Held

2.01M

Put Options Held

2.84M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.82B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account